Literature DB >> 10822522

The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis.

M Alecu1, L Geleriu, G Coman, L Gălăţescu.   

Abstract

Serological level of interleukin-1 (IL-1), Interleukin-2 (IL-2), Interleukin-6 (IL-6) and tumour necrosis factor (TNF) alpha was investigated in 26 patients with scleroderma, divided into three lots, by the extension and the progress of the disease. Determinations were performed by ELISA in attack and in remission (after treatment with prednison). Normal values: IL-1 (0-5 pg/ml), IL-2 (0-5 pg/ml), IL-6 (5-15 pg/ml), TNF (0-16 pg/ml). Lot A. Results obtained at the first determination showed that IL-1 is elevated in 4 cases (10-15 pg/ml), IL-2 in 5 cases (10-32 pg/ml), IL-6 in 5 cases (15-42 pg/ml) and TNF in 4 cases (18-34 pg/ml). In the second determination IL-1 was increased in 1 case (8 pg/ml), IL-2 in 1 case (9 pg/ml), IL-6 in 2 cases (12 pg/ml) and TNF was normal. Lot B. In the first determination IL-1 was elevated in 5 cases (8-12 pg/ml), IL-2 in 5 cases (10-15 pg/ml), IL-6 in 7 cases (16-20 pg/ml) and TNF was raised in 3 cases (18-25 pg/ml). At the second determination IL-1 showed normal values in all the cases, IL-2 was raised in 2 cases (10 pg/ml), IL-6 in 2 cases (12.15 pg/ml), TNF in 1 case (20 pg/ml). Lot C. In the first determination there were raised values in 4 cases for IL-1 (6-8 pg/ml), 3 cases for IL-2 (10-18 pg/ml), 5 cases for IL-6 (18-20 pg/ml), 2 cases for TNF (20 pg/ml). At the second determination IL-2 was elevated in 1 case (10 pg/ml), IL-6 in 1 case (15 pg/ml). We consider that in scleroderma there is a disturbance of the investigated cytokines due to the activation and involvement of the secretory cells into the pathogenesis of the disease. The increase of the serological levels of IL-1, IL-2, IL-6 and TNF depends on the extension of the lesions and the clinical and biological activity periods of the disease. The absence of the increase of the serological levels does not exclude their activity at the lesional site.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10822522

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  14 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

2.  Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients.

Authors:  L Michel; D Farge; J Baraut; Z Marjanovic; F Jean-Louis; R Porcher; E I Grigore; C Deligny; F Romijn; L C M Arruda; J van Pelt; N Levarht; F Verrecchia; J M van Laar
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

3.  Post-stroke fatigue as an indicator of underlying bioenergetics alterations.

Authors:  N Jennifer Klinedinst; Rosemary Schuh; Steven J Kittner; William T Regenold; Glenn Kehs; Christine Hoch; Alisha Hackney; Gary Fiskum
Journal:  J Bioenerg Biomembr       Date:  2019-01-07       Impact factor: 2.945

Review 4.  Cytokine profiles in localized scleroderma and relationship to clinical features.

Authors:  Katherine Kurzinski; Kathryn S Torok
Journal:  Cytokine       Date:  2011-05-04       Impact factor: 3.861

5.  Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.

Authors:  Ayumi Yoshizaki; Kazuhiro Komura; Yohei Iwata; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Shinichi Sato
Journal:  J Clin Immunol       Date:  2008-09-30       Impact factor: 8.317

6.  Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features.

Authors:  K Takagi; Y Kawaguchi; M Hara; T Sugiura; M Harigai; N Kamatani
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

7.  Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort.

Authors:  Heidi Jacobe; Chul Ahn; Frank C Arnett; John D Reveille
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

8.  Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement.

Authors:  E Scala; S Pallotta; A Frezzolini; D Abeni; C Barbieri; F Sampogna; O De Pità; P Puddu; R Paganelli; G Russo
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

9.  Tumour necrosis factor-alpha production in fibrosing alveolitis is macrophage subset specific.

Authors:  P Pantelidis; D S McGrath; A M Southcott; C M Black; R M du Bois
Journal:  Respir Res       Date:  2001-10-08

10.  In vitro hematological and in vivo vasoactivity assessment of dextran functionalized graphene.

Authors:  Sayan Mullick Chowdhury; Shruti Kanakia; Jimmy D Toussaint; Mary D Frame; Anthony M Dewar; Kenneth R Shroyer; William Moore; Balaji Sitharaman
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.